IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Eric Weisblum, Founder and CEO of Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company.
Throughout the interview, Weisblum discussed Silo Pharma’s business model and recent milestones.
“Silo Pharma is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders,” Weisblum said. “We typically identify assets and look to partner with academic universities to advance their research with the goal of developing therapeutics to help patients down the road.”
“In 2021, we were able to license some very exciting technology and start advancing the research and development. We have partnerships with various universities,” he continued. “We have some technology in a partnership with Columbia University and University of Maryland, Baltimore, and we look forward to getting some data this year from the studies that we have initiated.”
Weisblum then discussed his background and those of the Silo Pharma leadership team.
“I have over 20 years’ experience investing in, building and managing businesses. I have served on numerous public companies’ boards and have been quite active in licensing technologies out of universities,” Weisblum added. “Our board of directors consists of two doctors and a gentleman with a finance background, and our scientific advisory board is led by Dr. Josh Wooley out of University of California, San Francisco and Dr. Charles Nemeroff, the head of the Department of Psychiatry and Behavioral Sciences at Dell Medical School at The University of Texas at Austin. We have a very well-balanced management team.”
Join IBN’s Stuart Smith and Eric Weisblum, Founder and CEO of Silo Pharma Inc. (OTCQB: SILO), to learn more about the markets the company is targeting with its current research, as well as its operational goals for the balance of 2022 and beyond.
To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information, visit the company’s website at www.SiloPharma.com.
IBN consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its Investor Brand Platform, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.